The Top 5 Biosimilar Articles for the Week of August 10

Hi, I’m Skylar Jeremias for The Center for Biosimilars®, your resource for clinical, regulatory, business, and policy news in the rapidly changing world of biosimilars.

Here are the top 5 biosimilar articles for the week of August 10, 2020.

5. Sandoz Rituximab Measures Up in DLBCL

Number 5: A rituximab biosimilar in diffuse large B-cell lymphoma (DLBCL) passes the real-world test with flying colors, according to Manfred Weslau, MD.

4. Samsung Bioepis Enters Breast and Gastric Market in Brazil

Number 4: Samsung Bioepis makes a move into the promising Brazilian market for biosimilars, which data suggest is one of the fastest-growing biosimilars markets among emerging nations.

3. Samsung Bioepis Appeals to Patients Through Package Design

Number 3: In an award-winning attempt to get closer to patients, Samsung Bioepis has replaced harsh typography with white backgrounds and gentle shapes on its new biosimilar packaging.

2. Anti-TNF Biologics Outperform in Crohn Disease

Number 2: A real-world study on inflammatory bowel disease employing originator and biosimilar biologics suggests anti—tumor necrosis factor (TNF) therapy may be more effective for Crohn disease than for ulcerative colitis.

1. Cadila Puts a Teriparatide Biosimilar on the Market

Number 1: Cadila Pharmaceuticals charges ahead with yet another biosimilar launch in India, an osteoporosis agent referencing Eli Lilly's teriparatide drug Forteo.

To read all of these articles and more, visit centerforbiosimilars.com.